Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.
Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.
Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.
Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering platform technologies, will announce its Q2 2024 financial results on August 6, 2024, after the U.S. market closes. The company invites investors to join a conference call at 4:30 p.m. Eastern Time, where management will discuss these results. Interested participants should register online in advance. A live and archived webcast of the call will be available on the MaxCyte website.
MaxCyte, a leader in cell-engineering technologies, announced its participation in the William Blair 44th Annual Growth Stock Conference. The event is scheduled for June 5th at 2:40 pm CT. The session will be available live and archived on MaxCyte's investor relations website. MaxCyte focuses on advancing cell-based therapeutics and bioprocessing applications, emphasizing discovery, development, and commercialization.
MaxCyte has signed a strategic platform license agreement with Legend Biotech to accelerate the discovery and development of cell therapies. Under this non-exclusive worldwide license, Legend Biotech will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for various cell types, including T cells and NK cells. MaxCyte will receive annual licensing fees, clinical development milestones, and royalties on net sales of the licensed products. This marks MaxCyte’s 28th clinical/commercial partnership, emphasizing its role in advancing cell-based therapeutics.
The partnership aims to enhance Legend Biotech’s non-viral engineered therapeutic pipeline, leveraging MaxCyte’s expertise in scalable cell engineering and regulatory support. The ExPERT™ platform provides high transfection efficiency and seamless scalability, essential for developing innovative cell therapies. Both companies aim to transform the treatment landscape and meet expanding clinical and commercial needs.
MaxCyte, Inc. reported a total revenue of $11.3 million in the first quarter of 2024, marking a 32% increase year-over-year. Core business revenue grew by 5% to $8.2 million. The company signed four Strategic Platform License (SPL) clients year-to-date, with a total of 27 partners. Cash, cash equivalents, and investments stood at $202.5 million as of March 31, 2024. MaxCyte affirmed its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $5 million in SPL Program-related revenue.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
